Pre-Exposure Prophylaxis

Although there is still no HIV vaccine and no promising candidates in the pipeline, data published throughout 2024 show the significant impacts of prevention efforts and tools.

Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work.

LOS ANGELES —In this video from IDWeek, Vani Vannappagari, MBBS, PhD, MPH, global head of epidemiology and real-world evidence at ViiV Healthcare, discusses study findings demonstrating the effectiveness of cabotegravir for HIV prevention.

LOS ANGELES — Lenacapavir, the twice-yearly injectable HIV drug, could potentially transform HIV prevention if it is approved as PrEP, research has shown.

Access to pre-exposure prophylaxis remains insufficient, especially among Black, Hispanic and Medicare-insured populations, results of an analysis presented at IDWeek suggested.

LIMA, Peru — In a finding described as “reassuring,” researchers detected no interaction between the long-acting HIV prevention drug cabotegravir and hormonal contraceptives among women enrolled in a large trial.

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

A 60-year-old man in Germany became the seventh person to be considered potentially cured of HIV after receiving a stem cell transplant from a person with a genetic mutation that prevents infection.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.